Neurocrine posts positive Phase II results with endometriosis drug
This article was originally published in Scrip
Executive Summary
Neurocrine's elagolix met its primary endpoints in patients with endometriosis in the Phase II Daisy PETAL study, show top-line results. The company's share price was up over 50% on Nasdaq, to $4.05 on 25 May 25, during pre-market trading on the news.